ClinicalTrials.gg
Enrolling by invitationNCT04762992HepaGrowthUpdated Aug 13, 2025

LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)

A Phase 3 interventional study of subcutaneous Enoxaparin and standard of care in Fetal Growth Retardation, Prematurity and Pre-Eclampsia, sponsored by Centro Hospitalar de Lisboa Central. Enrolling by invitation at 1 site in Portugal. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by Centro Hospitalar de Lisboa Central · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Early fetal growth restriction (FGR) is associated with considerable fetal and neonatal morbimortality. Placental thrombosis, infarcts and hypercoagulability are frequently seen in these pregnancies, suggesting a role for the activation of the coagulation cascade in the genesis of FGR. Patients will be randomized for low-molecular weight heparin or standard of care, and the outcomes of both arms (gestational age at delivery, gestational and fetal morbidity) will be compared.

Read the detailed description

FGR is the second leading cause of perinatal mortality, being associated with approximately 30% of stillbirths. Early FGR is associated with substantial disturbances of placental implantation and fetal hypoxia, which requires fetal cardiovascular adaptation. Both maternal and fetal Doppler alterations are present, allowing for risk stratification and monitoring. Although the precise etiology for FGR due to placental causes is unknown, placental thrombosis, infarcts and hypercoagulability are frequently seen, suggesting a role for the activation of the coagulation cascade in the genesis of FGR. Currently, the management of early FGR is limited to the monitoring of fetal Doppler parameters until the risks for preterm delivery outweight the benefits of ongoing monitoring. As such, there is a special need for effective preventive and therapeutic interventions that improve the outcomes. Low molecular weight heparin (LMWH), for its anticoagulant and anti-inflammatory properties has been suggested as a possible therapeutic agent in this setting. The investigators will randomize the participants to two intervention arms in a one-to-one ratio, using a computer generated randomization program. The randomization will be stratified for gestational age at diagnosis of FGR (22 to 26 weeks and >26 to 32 weeks). The experimental group will be administered enoxaparin subcutaneous injections (40 mg, 4000 IU daily) and the control group will be provided standard of care. Both groups will start intervention immediately after the diagnosis of FGR, and will continue it until 36 weeks of gestation or 12 hours before delivery, whichever comes first.

02

Conditions studied

  • Fetal Growth Retardation
  • Prematurity
  • Pre-Eclampsia

Keywords

  • Fetal Growth Retardation
  • Prematurity
  • Pre-Eclampsia
  • Placenta
03

In context

Fetal Growth Retardation

262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.

This study's planned enrollment of 12 is below the median of 150 across 110 interventional studies indexed under Fetal Growth Retardation.

Browse Fetal Growth Retardation studies →

Lead sponsor

Centro Hospitalar de Lisboa Central is the lead sponsor of 16 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. being 18 years old or older
  2. being able to provide consent
  3. having a viable singleton pregnancy with diagnosed early FGR confirmed in our unit according to the 2020 International Society of Ultrasound in Obstetrics \& Gynecology (ISUOG) criteria (one solitary parameter: estimated fetal weight/ abdominal circumference lower than the 3rd centile or absent end-diastolic flow in umbilical artery; or estimated fetal weight/abdominal circumference below the 10th centile combined with either umbilical artery pulsatility index > 95th centile or uterine artery mean pulsatility index > 95th centile)

Exclusion criteria

Exclusion Criteria:

  1. multiple gestation;
  2. diagnosed fetal chromosomal abnormalities;
  3. associated fetal morphological malformations;
  4. evidence of fetal infection (serological or after invasive testing);
  5. use of LMWH or NFH in the index pregnancy before randomization or start of any of these medications for another indication if the patient is in the control group
  6. present use of systemic salicylates in anti-inflammatory dosage (> 150mg/day) or NSAIDs (including ketorolac)
  7. maternal history of allergy to LMWH or non-fractionated heparin (NFH);
  8. to pork products;
  9. maternal history of heparin-induced thrombocytopenia;
  10. maternal thrombocytopenia ( \< 100 000);
  11. history of maternal hemophilia or Von Willebrand disease
  12. presence of placental hematoma;
  13. maternal diabetic retinopathy;
  14. bacterial endocarditis;
  15. active bleeding and conditions with a high risk of hemorrhage, including recent hemorrhagic stroke, gastrointestinal ulcer, presence of malignant neoplasm at high risk of bleeding, recent brain, spinal or ophthalmic surgery, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities;
  16. persistent blood pressure > 160/100 mmHg, despite optimal anti-hypertensive regimen;
  17. history of severe renal disease ( \<30mL/min);
  18. known or suspected hepatic impairment;
  19. current participation in another clinical trial;
  20. patients that are not part of the national health system (SNS);
  21. delivery already scheduled, or predicted in the next 7 days.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Intervention group, enoxaparin

    Enoxaparin subcutaneous injections

    Drug: subcutaneous Enoxaparin

  • Other
    Standard of care

    Obsteric standard of care

    Other: standard of care

Interventions

  • DrugEnoxaparinStudies of EnoxaparinEnoxaparin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.

    Also known as: experimental

  • Otherstandard of care

    Obsteric standard of care.

06

What researchers measure

Primary outcomes

  1. Gestational age at delivery

    Best assessment of the time of gestation, either by first trimester sonography, last menstrual day or day of implantation of in vitro conception product

    Time frame: day of delivery

Secondary outcomes

  1. Neonatal birtweight and birthweight centile

    Weight at birth of the newborn (in grams) and respective percentile

    Time frame: day of delivery

  2. Newborn Apgar Score in the 5th minute

    Newborn Apgar score in the 5th minute, assessed by a nurse or pediatrician

    Time frame: day of delivery

  3. Newborn Umbilical Artery pH

    pH of the umbilical artery, assessed immediately after delivery

    Time frame: day of delivery

  4. Stillbirth, neonatal intensive care admission and duration of admission

    A composite outcome of severe neonatal morbidity (evidence of one or more of: intraventricular hemorrhage grade 3 or 4; cystic periventricular leukomalacia; chronic lung disease; retinopathy of prematurity requiring treatment; necrotizingenterocolitis requiring surgery

    Time frame: from randomization up to 1 year after delivery

  5. Maternal and fetal Doppler parameters

    Pulsatility index (PI) of the uterine arteries, PI anddiastolic flow in the umbilical artery, PI in the middle cerebral artery, cerebro-placental ratio, ductusvenosus PI and a wave

    Time frame: from randomization to delivery

  6. Placental pathology

    Percentage of placenta occupied by fibrosis or infarcts

    Time frame: day of delivery

  7. Sflt1-PLGF ratio

    Evolution of Sflt1-PLGF ratio from diagnosis of FGR to delivery

    Time frame: from randomization to delivery

  8. Syncytiotrophoblast membrane extracellular vesicles (STB-EV)

    Protein and genetic composition

    Time frame: from randomization up to 1 week after delivery

  9. Gestational hypertension or preeclampsia; placental abruption

    Pregnancy induced hypertension, preeclamspia,HELLP syndrome

    Time frame: from randomization up to 1 week after delivery

  10. Antepartum hemorrhage; maternal thrombocytopenia (platelets < 100 000 x 10 9/L); postpartum hemorrhage

    Hemorrhage, bruising,pain

    Time frame: from randomization up to 1 week after delivery

  11. Mode and indication for delivery

    As spontaneous vaginal birth, operative vaginal birth (forceps orvacuum/ventouse), or cesarean section. For induced labor or planned cesarean section, theindication for scheduling the delivery will be documented (e.g., gestational age, maternal or fetalindications). In cases of operative vaginal or cesarean delivery, the indication for intervention willbe specified (e.g., non-reassuring fetal status, labor dystocia).

    Time frame: from randomization up to 48h after delivery

07

Study locations

1 site
  • Centro de Diagnóstico Pré-Natal, Maternidade Dr. Alfredo da Costa, Centro Hospitalar Universitário de Lisboa Central
    Lisbon, 1050-170, Portugal
08

References and documents

Publications

  • Miller J, Turan S, Baschat AA. Fetal growth restriction. Semin Perinatol. 2008 Aug;32(4):274-80. doi: 10.1053/j.semperi.2008.04.010. PubMed 18652928 ↗
  • Nardozza LMM, Zamarian ACP, Araujo Junior E. New Definition of Fetal Growth Restriction: Consensus Regarding a Major Obstetric Complication. Rev Bras Ginecol Obstet. 2017 Jul;39(7):315-316. doi: 10.1055/s-0037-1603741. Epub 2017 Jun 12. No abstract available. PubMed 28605820 ↗
  • Arbeille P, Maulik D, Fignon A, Stale H, Berson M, Bodard S, Locatelli A. Assessment of the fetal PO2 changes by cerebral and umbilical Doppler on lamb fetuses during acute hypoxia. Ultrasound Med Biol. 1995;21(7):861-70. doi: 10.1016/0301-5629(95)00025-m. PubMed 7491742 ↗
  • Nardozza LM, Caetano AC, Zamarian AC, Mazzola JB, Silva CP, Marcal VM, Lobo TF, Peixoto AB, Araujo Junior E. Fetal growth restriction: current knowledge. Arch Gynecol Obstet. 2017 May;295(5):1061-1077. doi: 10.1007/s00404-017-4341-9. Epub 2017 Mar 11. PubMed 28285426 ↗
  • Elder MG, Myatt L. Coagulation and fibrinolysis in pregnancies complicated by fetal growth retardation. Br J Obstet Gynaecol. 1976 May;83(5):355-60. doi: 10.1111/j.1471-0528.1976.tb00842.x. PubMed 1268144 ↗
  • Bellart J, Gilabert R, Fontcuberta J, Carreras E, Miralles RM, Cabero L. Coagulation and fibrinolytic parameters in normal pregnancy and in pregnancy complicated by intrauterine growth retardation. Am J Perinatol. 1998 Feb;15(2):81-5. doi: 10.1055/s-2007-993903. PubMed 9514130 ↗
  • Fuke Y, Aono T, Imai S, Suehara N, Fujita T, Nakayama M. Clinical significance and treatment of massive intervillous fibrin deposition associated with recurrent fetal growth retardation. Gynecol Obstet Invest. 1994;38(1):5-9. doi: 10.1159/000292434. PubMed 7959327 ↗
  • Seravalli V, Baschat AA. A uniform management approach to optimize outcome in fetal growth restriction. Obstet Gynecol Clin North Am. 2015 Jun;42(2):275-88. doi: 10.1016/j.ogc.2015.01.005. PubMed 26002166 ↗
  • Tyrell DJ, Kilfeather S, Page CP. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci. 1995 Jun;16(6):198-204. doi: 10.1016/s0165-6147(00)89022-7. PubMed 7652929 ↗
  • Lewander R, Lunell NO, Nylund L, Sarby B, Thornstrom S. [Uterine-placental blood flow. Method of measurement and clinical use]. Lakartidningen. 1980 Jan 30;77(5):333-4. No abstract available. Swedish. PubMed 7366291 ↗
  • Seravalli V, Block-Abraham DM, Turan OM, Doyle LE, Blitzer MG, Baschat AA. Second-trimester prediction of delivery of a small-for-gestational-age neonate: integrating sequential Doppler information, fetal biometry, and maternal characteristics. Prenat Diagn. 2014 Nov;34(11):1037-43. doi: 10.1002/pd.4418. Epub 2014 Jun 11. PubMed 24864018 ↗
  • Picklesimer AH, Oepkes D, Moise KJ Jr, Kush ML, Weiner CP, Harman CR, Baschat AA. Determinants of the middle cerebral artery peak systolic velocity in the human fetus. Am J Obstet Gynecol. 2007 Nov;197(5):526.e1-4. doi: 10.1016/j.ajog.2007.04.002. PubMed 17980196 ↗
  • Yu YH, Shen LY, Zou H, Wang ZJ, Gong SP. Heparin for patients with growth restricted fetus: a prospective randomized controlled trial. J Matern Fetal Neonatal Med. 2010 Sep;23(9):980-7. doi: 10.3109/14767050903443459. PubMed 19951008 ↗
  • Yu YH, Shen LY, Zhong M, Zhang Y, Su GD, Gao YF, Quan S, Zeng L. [Effect of heparin on fetal growth restriction]. Zhonghua Fu Chan Ke Za Zhi. 2004 Dec;39(12):793-6. Chinese. PubMed 15733401 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Jul 2026, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2021
First posted
Feb 21, 2021
StartActual
Jul 18, 2022
Primary completionEst.
Jul 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Aug 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04762992
Lead sponsor
Centro Hospitalar de Lisboa Central
Collaborators
NOVA Medical School
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
Jul 18, 2022
Primary completion
Jul 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Aug 13, 2025

Study contacts

Fátima Serrano, MD, PhD
study chair · Centro Hospitalar Universitário de Lisboa Central
Catarina Palma-dos-Reis, MD, MSc
principal investigator · Centro Hospitalar Universitário de Lisboa Central

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin

Start the discussion